Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Abrams, H. L., Spiro, R., & Goldstein, N. (1950). Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer, 3(1), 74-85. doi:10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7

Ahn, S. H., Kim, J. H., Baek, S. H., Kim, H., Cho, Y. Y., Suh, S., . . . Song, K. H. (2018). Characteristics of Adrenal Incidentalomas in a Large, Prospective Computed Tomography-Based Multicenter Study: The COAR Study in Korea. Yonsei Med J, 59(4), 501-510. doi:10.3349/ymj.2018.59.4.501

Alvarez-Morujo, R. J., Ruiz, M. A., Serafini, D. P., Delgado, I. L., Friedlander, E., & Yurrita, B. S. (2016). Management of multicentric paragangliomas: Review of 24 patients with 60 tumors. Head Neck, 38(2), 267-276. doi:10.1002/hed.23894

Amar, L., Lussey-Lepoutre, C., Lenders, J. W., Djadi-Prat, J., Plouin, P. F., & Steichen, O. (2016). MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol, 175(4), R135-145. doi:10.1530/eje-16-0189

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., . . . Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 67(2), 93-99. doi:10.3322/caac.21388

Ardito, A., Massaglia, C., Pelosi, E., Zaggia, B., Basile, V., Brambilla, R., . . . Terzolo, M. (2015). 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol, 173(6), 749-756. doi:10.1530/EJE-15-0707

Bancos, I., Alahdab, F., Crowley, R. K., Chortis, V., Delivanis, D. A., Erickson, D., . . . Murad, M. H. (2016). THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. Eur J Endocrinol, 175(6), R283-R295. doi:10.1530/EJE-16-0465

Bancos, I., Tamhane, S., Shah, M., Delivanis, D. A., Alahdab, F., Arlt, W., . . . Murad, M. H. (2016). DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. Eur J Endocrinol, 175(2), R65-80. doi:10.1530/eje-16-0297

Berruti, A., Grisanti, S., Pulzer, A., Claps, M., Daffara, F., Loli, P., . . . Terzolo, M. (2017). Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab, 102(4), 1358-1365. doi:10.1210/jc.2016-2894

Besemer, F., Pereira, A. M., & Smit, J. W. (2011). Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse. Neth J Med, 69(7), 318-323. 

Bharwani, N., Rockall, A. G., Sahdev, A., Gueorguiev, M., Drake, W., Grossman, A. B., & Reznek, R. H. (2011). Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol, 196(6), W706-714. doi:10.2214/AJR.10.5540

Binderup, M. L., Bisgaard, M. L., Harbud, V., Moller, H. U., Gimsing, S., Friis-Hansen, L., . . . Danish v, H. L. C. G. (2013). Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J, 60(12), B4763. 

Boland, G. W., Dwamena, B. A., Jagtiani Sangwaiya, M., Goehler, A. G., Blake, M. A., Hahn, P. F., . . . Kalra, M. K. (2011). Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology, 259(1), 117-126. doi:10.1148/radiol.11100569

Boland, G. W., Lee, M. J., Gazelle, G. S., Halpern, E. F., McNicholas, M. M., & Mueller, P. R. (1998). Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol, 171(1), 201-204. doi:10.2214/ajr.171.1.9648789 [doi]

Burnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., . . . Gimenez-Roqueplo, A. P. (2009). The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab, 94(8), 2817-2827. doi:10.1210/jc.2008-2504

Catena, C., Colussi, G., Lapenna, R., Nadalini, E., Chiuch, A., Gianfagna, P., & Sechi, L. A. (2007). Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension, 50(5), 911-918. doi:10.1161/hypertensionaha.107.095448

Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., & Sechi, L. A. (2008). Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med, 168(1), 80-85. doi:10.1001/archinternmed.2007.33

Chan, K. C. A., Lit, L. C. W., Law, E. L. K., Tai, M. H. L., Yung, C. U., Chan, M. H. M., & Lam, C. W. K. (2004). Diminished Urinary Free Cortisol Excretion in Patients with Moderate and Severe Renal Impairment. Clinical Chemistry, 50(4), 757-759. doi:10.1373/clinchem.2003.029934

Chao, C. T., Wu, V. C., Kuo, C. C., Lin, Y. H., Chang, C. C., Chueh, S. J., . . . Stowasser, M. (2013). Diagnosis and management of primary aldosteronism: an updated review. Ann Med, 45(4), 375-383. doi:10.3109/07853890.2013.785234

Choi, M., Scholl, U. I., Yue, P., Bjorklund, P., Zhao, B., Nelson-Williams, C., . . . Lifton, R. P. (2011). K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science, 331(6018), 768-772. doi:10.1126/science.1198785

Di Dalmazi, G., Pasquali, R., Beuschlein, F., & Reincke, M. (2015). Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur J Endocrinol, 173(4), M61-71. doi:10.1530/EJE-15-0272

Dinnes, J., Bancos, I., Ferrante di Ruffano, L., Chortis, V., Davenport, C., Bayliss, S., . . . Arlt, W. (2016). MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol, 175(2), R51-64. doi:10.1530/EJE-16-0461

Dixon, R. B., & Christy, N. P. (1980). On the various forms of corticosteroid withdrawal syndrome. Am J Med, 68(2), 224-230. 

Dorn, L. D., Burgess, E. S., Friedman, T. C., Dubbert, B., Gold, P. W., & Chrousos, G. P. (1997). The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab, 82(3), 912-919. doi:10.1210/jcem.82.3.3834

Douma, S., Petidis, K., Doumas, M., Papaefthimiou, P., Triantafyllou, A., Kartali, N., . . . Zamboulis, C. (2008). Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet, 371(9628), 1921-1926. doi:10.1016/S0140-6736(08)60834-X

Edwin, B., Raeder, I., Trondsen, E., Kaaresen, R., & Buanes, T. (2001). Outpatient laparoscopic adrenalectomy in patients with Conn's syndrome. Surg Endosc, 15(6), 589-591. doi:10.1007/s004640090021

Eisenhofer, G., Peitzsch, M., Kaden, D., Langton, K., Mangelis, A., Pamporaki, C., . . . Lenders, J. W. M. (2019). Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin Chim Acta, 490, 46-54. doi:10.1016/j.cca.2018.12.019

El-Farhan, N., Pickett, A., Ducroq, D., Bailey, C., Mitchem, K., Morgan, N., . . . Rees, D. A. (2013). Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf), 78(5), 673-680. doi:10.1111/cen.12039

Evans, D. G. R., Salvador, H., Chang, V. Y., Erez, A., Voss, S. D., Schneider, K. W., . . . Tabori, U. (2017). Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clin Cancer Res, 23(12), e46-e53. doi:10.1158/1078-0432.CCR-17-0589

Falhammar, H., Kjellman, M., & Calissendorff, J. (2018). Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect, 7(1), 186-192. doi:10.1530/ec-17-0321

Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., . . . Dekkers, O. M. (2016). Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol, 175(2), G1-G34. doi:10.1530/EJE-16-0467

Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R., . . . Terzolo, M. (2018). European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol, 179(4), G1-G46. doi:10.1530/EJE-18-0608

Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., . . . Group, F.-A. S. (2012). Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 366(23), 2189-2197. doi:10.1056/NEJMoa1200966

Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., . . . Kirby, A. (2007). Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2), 81-88. doi:10.1136/jmg.2006.045906

Fisch, U. (1978). Infratemporal fossa approach to tumours of the temporal bone and base of the skull. J Laryngol Otol, 92(11), 949-967. 

Fischer, E., Hanslik, G., Pallauf, A., Degenhart, C., Linsenmaier, U., Beuschlein, F., . . . Reincke, M. (2012). Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab, 97(11), 3965-3973. doi:10.1210/jc.2012-2234

Fourkiotis, V., Vonend, O., Diederich, S., Fischer, E., Lang, K., Endres, S., . . . Mephisto Study, G. (2013). Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol, 168(1), 75-81. doi:10.1530/EJE-12-0631

Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., . . . Young, W. F., Jr. (2016). The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 101(5), 1889-1916. doi:10.1210/jc.2015-4061

Gouli, A., Kaltsas, G., Tzonou, A., Markou, A., Androulakis, II, Ragkou, D., . . . Piaditis, G. (2011). High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest, 41(11), 1227-1236. doi:10.1111/j.1365-2362.2011.02531.x

Groussin, L., Bonardel, G., Silvera, S., Tissier, F., Coste, J., Abiven, G., . . . Tenenbaum, F. (2009). 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab, 94(5), 1713-1722. doi:10.1210/jc.2008-2302

Guss, Z. D., Batra, S., Limb, C. J., Li, G., Sughrue, M. E., Redmond, K., . . . Lim, M. (2011). Radiosurgery of glomus jugulare tumors: a meta-analysis. Int J Radiat Oncol Biol Phys, 81(4), e497-502. doi:10.1016/j.ijrobp.2011.05.006

Hammarstedt, L., Muth, A., Sigurjonsdottir, H. A., Almqvist, E., Wangberg, B., Hellstrom, M., & Adrenal Study Group of Western, S. (2012). Adrenal lesions in patients with extra-adrenal malignancy - benign or malignant? Acta Oncol, 51(2), 215-221. doi:10.3109/0284186X.2011.608084

Hammarstedt, L., Muth, A., Wangberg, B., Bjorneld, L., Sigurjonsdottir, H. A., Gotherstrom, G., . . . Hellstrom, M. (2010). Adrenal lesion frequency: A prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol, 51(10), 1149-1156. doi:10.3109/02841851.2010.516016

Hannemann, A., & Wallaschofski, H. (2012). Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. Horm Metab Res, 44(3), 157-162. doi:10.1055/s-0031-1295438

Hennings, J., Lindhe, O., Bergstrom, M., Langstrom, B., Sundin, A., & Hellman, P. (2006). [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab, 91(4), 1410-1414. doi:10.1210/jc.2005-2273

Hines, J. M., Bancos, I., Bancos, C., Singh, R. D., Avula, A. V., Young, W. F., . . . Singh, R. J. (2017). High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders. Clin Chem, 63(12), 1824-1835. doi:10.1373/clinchem.2017.271106

Hirsch, D., Shimon, I., Manisterski, Y., Aviran-Barak, N., Amitai, O., Nadler, V., . . . Tsvetov, G. (2018). Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's. Endocrine, 62(3), 712-720. doi:10.1007/s12020-018-1709-y

Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018a). Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol, 6(1), 51-59. doi:10.1016/s2213-8587(17)30367-4

Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018b). Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol, 3(8), 768-774. doi:10.1001/jamacardio.2018.2003

Ito, Y., Takeda, R., Karashima, S., Yamamoto, Y., Yoneda, T., & Takeda, Y. (2011). Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res, 34(1), 98-102. doi:10.1038/hr.2010.166

Jakobsson, H., Farmaki, K., Sakinis, A., Ehn, O., Johannsson, G., & Ragnarsson, O. (2018). Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagn Interv Radiol, 24(2), 89-93. doi:10.5152/dir.2018.17397

Kamilaris, C. D. C., & Stratakis, C. A. (2018). An update on adrenal endocrinology: significant discoveries in the last 10 years and where the field is heading in the next decade. Hormones (Athens), 17(4), 479-490. doi:10.1007/s42000-018-0072-y

Kawamata, A., Iihara, M., Okamoto, T., & Obara, T. (2008). Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World J Surg, 32(5), 890-896. doi:10.1007/s00268-007-9394-7

Kayser, S. C., Dekkers, T., Groenewoud, H. J., van der Wilt, G. J., Carel Bakx, J., van der Wel, M. C., . . . Deinum, J. (2016). Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab, 101(7), 2826-2835. doi:10.1210/jc.2016-1472

Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., . . . Naruse, M. (2014). Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer, 21(3), 405-414. doi:10.1530/erc-13-0494

Kloos, R. T., Gross, M. D., Francis, I. R., Korobkin, M., & Shapiro, B. (1995). Incidentally discovered adrenal masses. Endocr Rev, 16(4), 460-484. doi:10.1210/edrv-16-4-460

Krych, A. J., Foote, R. L., Brown, P. D., Garces, Y. I., & Link, M. J. (2006). Long-term results of irradiation for paraganglioma. Int J Radiat Oncol Biol Phys, 65(4), 1063-1066. doi:10.1016/j.ijrobp.2006.02.020

Lam, K. Y., & Lo, C. Y. (2002). Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf), 56(1), 95-101. 

Lattouf, J. B., Pautler, S. E., Reaume, M. N., Kim, R. H., Care, M., Green, J., . . . Kidney Cancer Research Network of, C. (2016). Structured assessment and followup for patients with hereditary kidney tumour syndromes. Can Urol Assoc J, 10(7-8), E214-E222. doi:10.5489/cuaj.3798

Lenders, J. W., Duh, Q. Y., Eisenhofer, G., Gimenez-Roqueplo, A. P., Grebe, S. K., Murad, M. H., . . . Young, W. F., Jr. (2014). Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 99(6), 1915-1942. doi:10.1210/jc.2014-1498

Lloyd, R. V., Osamura, R. Y., Klöppel, G., Rosai, J., Bosman, F. T., Jaffe, E. S., . . . Ohgaki, H. (2017). WHO classification of tumours of endocrine organs. Lyon: International Agency for Research on Cancer.

Manoharan, J., Albers, M. B., & Bartsch, D. K. (2017). The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer, 24(10), T209-T225. doi:10.1530/ERC-17-0231

Martin, T. P., Irving, R. M., & Maher, E. R. (2007). The genetics of paragangliomas: a review. Clin Otolaryngol, 32(1), 7-11. doi:10.1111/j.1365-2273.2007.01378.x

Mendenhall, W. M., Amdur, R. J., Vaysberg, M., Mendenhall, C. M., & Werning, J. W. (2011). Head and neck paragangliomas. Head Neck, 33(10), 1530-1534. doi:10.1002/hed.21524

Mericq, M. V., & Cutler, G. B., Jr. (1998). High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab, 83(2), 682-684. doi:10.1210/jcem.83.2.4555

Milliez, P., Girerd, X., Plouin, P. F., Blacher, J., Safar, M. E., & Mourad, J. J. (2005). Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 45(8), 1243-1248. doi:10.1016/j.jacc.2005.01.015

Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018). Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 6(1), 41-50. doi:10.1016/S2213-8587(17)30319-4

Monticone, S., Viola, A., Rossato, D., Veglio, F., Reincke, M., Gomez-Sanchez, C., & Mulatero, P. (2015). Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol, 3(4), 296-303. doi:10.1016/s2213-8587(14)70069-5

Morelli, V., Reimondo, G., Giordano, R., Della Casa, S., Policola, C., Palmieri, S., . . . Chiodini, I. (2014). Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab, 99(3), 827-834. doi:10.1210/jc.2013-3527

Mosso, L., Carvajal, C., Gonzalez, A., Barraza, A., Avila, F., Montero, J., . . . Fardella, C. E. (2003). Primary aldosteronism and hypertensive disease. Hypertension, 42(2), 161-165. doi:10.1161/01.HYP.0000079505.25750.11

Mulatero, P., Monticone, S., Bertello, C., Mengozzi, G., Tizzani, D., Iannaccone, A., & Veglio, F. (2010). Confirmatory tests in the diagnosis of primary aldosteronism. Horm Metab Res, 42(6), 406-410. doi:10.1055/s-0029-1246186

Mulatero, P., Stowasser, M., Loh, K. C., Fardella, C. E., Gordon, R. D., Mosso, L., . . . Young, W. F., Jr. (2004). Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab, 89(3), 1045-1050. doi:10.1210/jc.2003-031337

Mulatero, P., Tizzani, D., Viola, A., Bertello, C., Monticone, S., Mengozzi, G., . . . Veglio, F. (2011). Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension, 58(5), 797-803. doi:10.1161/HYPERTENSIONAHA.111.175083

Muth, A., Crona, J., Gimm, O., Elmgren, A., Filipsson, K., Stenmark Askmalm, M., . . . Tham, E. (2019). Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med, 285(2), 187-204. doi:10.1111/joim.12869

Muth, A., Hammarstedt, L., Hellstrom, M., Nyman, U., Sundin, A., Wahrenberg, H., & Wangberg, B. (2017). [Swedish guidelines for the management of adrenal incidentalomas]. Lakartidningen, 114. 

Muth, A., Hammarstedt, L., Hellstrom, M., Sigurjonsdottir, H. A., Almqvist, E., Wangberg, B., & Adrenal Study Group of Western, S. (2011). Cohort study of patients with adrenal lesions discovered incidentally. Br J Surg, 98(10), 1383-1391. doi:10.1002/bjs.7566

Muth, A., Ragnarsson, O., Johannsson, G., & Wangberg, B. (2015). Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg, 102(4), 307-317. doi:10.1002/bjs.9744

Nieman, L. K., Biller, B. M., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., . . . Endocrine, S. (2015). Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 100(8), 2807-2831. doi:10.1210/jc.2015-1818

Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., . . . Loren, A. W. (2018). Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 36(19), 1994-2001. doi:10.1200/jco.2018.78.1914

Olsen, H., Nordenstrom, E., Bergenfelz, A., Nyman, U., Valdemarsson, S., & Palmqvist, E. (2012). Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine, 42(1), 164-173. doi:10.1007/s12020-012-9622-2

Park, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., . . . Valteau-Couanet, D. (2017). Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol, 35(22), 2580-2587. doi:10.1200/jco.2016.72.0177

Parker, K. J., Lerner, R. M., & Waag, R. C. (1988). Comparison of techniques for in vivo attenuation measurements. IEEE Trans Biomed Eng, 35(12), 1064-1068. doi:10.1109/10.8691

Parthasarathy, H. K., Menard, J., White, W. B., Young, W. F., Jr., Williams, G. H., Williams, B., . . . MacDonald, T. M. (2011). A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens, 29(5), 980-990. doi:10.1097/HJH.0b013e3283455ca5

Pellitteri, P. K., Rinaldo, A., Myssiorek, D., Gary Jackson, C., Bradley, P. J., Devaney, K. O., . . . Ferlito, A. (2004). Paragangliomas of the head and neck. Oral Oncol, 40(6), 563-575. doi:10.1016/j.oraloncology.2003.09.004

Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W., . . . Steichen, O. (2016). European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol, 174(5), G1-g10. doi:10.1530/eje-16-0033

Quayle, F. J., Spitler, J. A., Pierce, R. A., Lairmore, T. C., Moley, J. F., & Brunt, L. M. (2007). Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery, 142(4), 497-502; discussion 502-494. doi:10.1016/j.surg.2007.07.013

Rednam, S. P., Erez, A., Druker, H., Janeway, K. A., Kamihara, J., Kohlmann, W. K., . . . Wasserman, J. D. (2017). Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res, 23(12), e68-e75. doi:10.1158/1078-0432.ccr-17-0547

Reincke, M., Nieke, J., Krestin, G. P., Saeger, W., Allolio, B., & Winkelmann, W. (1992). Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. J Clin Endocrinol Metab, 75(3), 826-832. doi:10.1210/jcem.75.3.1517373

Ross, N. S., & Aron, D. C. (1990). Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med, 323(20), 1401-1405. doi:10.1056/NEJM199011153232007

Rossi, G. P., Auchus, R. J., Brown, M., Lenders, J. W., Naruse, M., Plouin, P. F., . . . Young, W. F., Jr. (2014). An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension, 63(1), 151-160. doi:10.1161/hypertensionaha.113.02097

Rossi, G. P., Cesari, M., Cuspidi, C., Maiolino, G., Cicala, M. V., Bisogni, V., . . . Pessina, A. C. (2013). Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension, 62(1), 62-69. doi:10.1161/hypertensionaha.113.01316

Scholl, U. I., Goh, G., Stolting, G., de Oliveira, R. C., Choi, M., Overton, J. D., . . . Lifton, R. P. (2013). Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet, 45(9), 1050-1054. doi:10.1038/ng.2695

Scholl, U. I., Stolting, G., Nelson-Williams, C., Vichot, A. A., Choi, M., Loring, E., . . . Lifton, R. P. (2015). Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife, 4, e06315. doi:10.7554/eLife.06315

Scholl, U. I., Stolting, G., Schewe, J., Thiel, A., Tan, H., Nelson-Williams, C., . . . Lifton, R. P. (2018). CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet, 50(3), 349-354. doi:10.1038/s41588-018-0048-5

Schultz, K. A. P., Rednam, S. P., Kamihara, J., Doros, L., Achatz, M. I., Wasserman, J. D., . . . Foulkes, W. D. (2017). PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res, 23(12), e76-e82. doi:10.1158/1078-0432.ccr-17-0629

Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., & Catena, C. (2006). Long-term renal outcomes in patients with primary aldosteronism. JAMA, 295(22), 2638-2645. doi:10.1001/jama.295.22.2638

Sethi, R. V., Sethi, R. K., Herr, M. W., & Deschler, D. G. (2013). Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators. Am J Otolaryngol, 34(5), 431-438. doi:10.1016/j.amjoto.2013.03.010

Shamblin, W. R., ReMine, W. H., Sheps, S. G., & Harrison, E. G., Jr. (1971). Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg, 122(6), 732-739. 

Sigurjonsdottir, H. A., Gronowitz, M., Andersson, O., Eggertsen, R., Herlitz, H., Sakinis, A., . . . Johannsson, G. (2012). Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study. BMC Endocr Disord, 12, 17. doi:10.1186/1472-6823-12-17

Song, J. H., Chaudhry, F. S., & Mayo-Smith, W. W. (2008). The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol, 190(5), 1163-1168. doi:10.2214/AJR.07.2799

Stowasser, M., & Gordon, R. D. (2016). Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiol Rev, 96(4), 1327-1384. doi:10.1152/physrev.00026.2015

Sturgeon, C., Shen, W. T., Clark, O. H., Duh, Q. Y., & Kebebew, E. (2006). Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg, 202(3), 423-430. doi:10.1016/j.jamcollsurg.2005.11.005

Sundin, A. (2012). Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics, 2(5), 516-522. doi:10.7150/thno.3613

Taieb, D., & Pacak, K. (2019). Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging, 46(11), 2223-2224. doi:10.1007/s00259-019-04435-z

Taylor, D. R., Ghataore, L., Couchman, L., Vincent, R. P., Whitelaw, B., Lewis, D., . . . Taylor, N. F. (2017). A 13-Steroid Serum Panel Based on LC-MS/MS: Use in Detection of Adrenocortical Carcinoma. Clin Chem, 63(12), 1836-1846. doi:10.1373/clinchem.2017.277624

Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., . . . Endocrine, S. (2012). Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab, 97(9), 2990-3011. doi:10.1210/jc.2012-1230

Thompson, L. D. (2002). Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol, 26(5), 551-566. 

Ueland, G. A., Methlie, P., Kellmann, R., Bjorgaas, M., Asvold, B. O., Thorstensen, K., . . . Husebye, E. S. (2017). Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol, 176(6), 705-713. doi:10.1530/eje-17-0078

Valassi, E., Santos, A., Yaneva, M., Toth, M., Strasburger, C. J., Chanson, P., . . . Webb, S. M. (2011). The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol, 165(3), 383-392. doi:10.1530/eje-11-0272

Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., . . . Mann, K. (2006). Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery, 140(6), 943-948; discussion 948-950. doi:10.1016/j.surg.2006.07.039

van den Berg, R., Verbist, B. M., Mertens, B. J., van der Mey, A. G., & van Buchem, M. A. (2004). Head and neck paragangliomas: improved tumor detection using contrast-enhanced 3D time-of-flight MR angiography as compared with fat-suppressed MR imaging techniques. AJNR Am J Neuroradiol, 25(5), 863-870. 

van der Linden, P., Steichen, O., Zinzindohoue, F., & Plouin, P. F. (2012). Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study. J Hypertens, 30(4), 761-769. doi:10.1097/HJH.0b013e328350225d

van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M., & Corssmit, E. P. (2014). (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf), 80(4), 487-501. doi:10.1111/cen.12341

Wells, S. A., Jr., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., . . . American Thyroid Association Guidelines Task Force on Medullary Thyroid, C. (2015). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 25(6), 567-610. doi:10.1089/thy.2014.0335

Westerdahl, C., Bergenfelz, A., Isaksson, A., Nerbrand, C., & Valdemarsson, S. (2011). Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim Health Care, 29(1), 57-62. doi:10.3109/02813432.2011.554015

Westerdahl, C., Bergenfelz, A., Isaksson, A., Wihl, A., Nerbrand, C., & Valdemarsson, S. (2006). High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care, 24(3), 154-159. doi:10.1080/02813430600830931

Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., . . . Primary Aldosteronism Surgery Outcome, i. (2017). Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol, 5(9), 689-699. doi:10.1016/S2213-8587(17)30135-3

Williams, T. A., & Reincke, M. (2018). MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol, 179(1), R19-R29. doi:10.1530/EJE-17-0990

Volpe, C., Hoog, A., Ogishima, T., Mukai, K., Lu, M., Thoren, M., & Hamberger, B. (2013). Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. J Clin Pathol, 66(4), 351-354. doi:10.1136/jclinpath-2012-201287

Yeomans, H., Calissendorff, J., Volpe, C., Falhammar, H., & Mannheimer, B. (2015). Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study. BMC Endocr Disord, 15, 6. doi:10.1186/s12902-015-0001-x

Young, W. F., Jr. (2019). Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med, 285(2), 126-148. doi:10.1111/joim.12831

Zeiger, M. A., Fraker, D. L., Pass, H. I., Nieman, L. K., Cutler, G. B., Jr., Chrousos, G. P., & Norton, J. A. (1993). Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery, 114(6), 1138-1143. 

Zilbermint, M., Xekouki, P., Faucz, F. R., Berthon, A., Gkourogianni, A., Schernthaner-Reiter, M. H., . . . Stratakis, C. A. (2015). Primary Aldosteronism and ARMC5 Variants. J Clin Endocrinol Metab, 100(6), E900-909. doi:10.1210/jc.2014-4167

Nästa kapitel
22 Vårdprogramgruppen